A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis

Abstract

Background: Moderate to severe plaque psoriasis (with or without psoriatic arthritis) places significant burden on patients’ lives. Objective: Explore and document patients’ experiences of living with psoriasis, including symptoms, treatments, impact on daily lives and patient-reported functioning. Methods: In a US-based, non-interventional study, narrative interviews were conducted at baseline and again within 16 weeks. In interviews, patients with moderate to severe psoriasis indicated symptoms, ranked symptoms according to level of bother and indicated areas of their lives affected by psoriasis. Transcripts of interviews were coded for themes. Measurements of psoriasis severity including BSA, PGA and PASI were recorded. Results: Symptoms reported most frequently included flaking/scaling (non-scalp areas), itching/scratching and rash, while the most bothersome symptoms were itching/scratching, flaking/scaling (non-scalp areas) and skin pain. Frequently reported impact areas were social and emotional. Conclusion: Broad-reaching interviews with patients with psoriasis show that these patients suffer in many aspects of their lives and in ways not indicated by typical psoriasis severity measures. Patients with psoriatic arthritis reported symptoms and disease-related complications at higher rates than those without arthritis. Physicians’ explorations of the effect of psoriasis on patients’ life events could aid in managing these patients.

Impact and management of depression in psoriasis patients

“…Psoriasis impairs social, physical, and emotional functioning [2]. The impact on the quality of life may cause depression, which in turn negatively affects adherence to treatment.…”

“…Psoriasis causes emotional and social burdens [1,2]. Psoriasis patients are 1.5 times more likely to experience depression compared to those without psoriasis (odds ratio 1.57; 95% confidence interval 1.40-1.76) [3].…”

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

“…Patients with psoriasis are also at risk of psoriatic arthritis, infection, obesity, hypertension, diabetes mellitus, hypercholesterolaemia, cancer, depression, disfiguration and disability . These clinical sequelae affect patients’ personal health, work productivity, quality of life (QoL) and interpersonal relationships throughout their lives …”

Patient benefits in the treatment of psoriasis: long‐term outcomes in German routine care 2007–2014

“…Patient burden and cumulative life course impairments are characteristic features of psoriasis, a systemic inflammatory disease affecting 2–3% of western populations, including a marked number of children . Management has changed considerably during the last decade.…”